Evidence map›Paper›PMID 35754025›Full record

SynthesisBMC gastroenterology2022

Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening: a meta-analysis.

Lixing Wang, Yu Liu, Duohan Zhang, Xiaoliang Xiong, Tingting Hao, Lili Zhong, Yinlong Zhao

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lixing WangDepartment of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China.
Yu LiuDepartment of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China.
Duohan ZhangDepartment of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China.
Xiaoliang XiongDepartment of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China.
Tingting HaoDepartment of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China.
Lili Zhong *Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, 130041, China. zhongll@jlu.edu.cn.
Yinlong Zhao *Department of Nuclear Medicine, The Second Hospital of Jilin University, Changchun, 130041, China. yinlong@jlu.edu.cn.
Second Affiliated Hospital of Jilin University · CN

Funding

Bethune Project No. 419161900018Special Health Project of Jilin Province No. 2020SCZT061Special Health Project of Jilin Provincial Finance Department 3D518V613429Special Project of Medical and Health Personnel in Jilin Province No. 2019SCZT026
6 · The paper itself

Abstract

backgroundA growing body of research suggests that methylated genes can be used as early diagnostic markers for cancer. Some studies on methylated Syndecan 2 (SDC2) have shown that it has a great diagnostic ability in colorectal cancer. This meta-analysis was aimed to estimate the diagnostic performance of methylated SDC2 as a potential novel biomarker to screen for the colorectal cancer.

methodsTwo independent researchers conducted a comprehensive literature search to identify all relevant studies on SDC2 methylation for the diagnosis of colorectal cancer from inception to March 1, 2021. By using STATA and Revman software, the data were analyzed using a Bivariate mixed model. The quality of each study was also evaluated.

resultsA total of 12 studies comprised of 1574 colorectal cancer patients and 1945 healthy people were included in our meta-analysis. Bivariate analysis showed a pooled sensitivity of 0.81 [95% confidence interval (CI) 0.74-0.86], specificity of 0.95 (95% CI 0.93-0.96), positive likelihood ratio of 15.29 (95% CI 10.83-21.60), and negative likelihood ratio of 0.21 (95% CI 0.15-0.27). The diagnostic odds ratio and the area under the summary ROC curve for diagnosing colorectal cancer were 74.42 (95% CI45.44-121.89) and 0.96 (95% CI 0.94-0.97), respectively. For adenomas, the pooled sensitivity and specificity were 0.47 (95% CI 0.34-0.61) and 0.95 (95% CI 0.92-0.97), respectively.

conclusionsOur analysis revealed that methylated SDC2 could be considered as a potential novel biomarker to screen for colorectal cancer.

Indexed as

Colorectal NeoplasmsSyndecan-2Biomarkers, TumorDNADNA MethylationEarly Detection of CancerHumansSensitivity and SpecificityBiomarkers, TumorDNASDC2 protein, humanSyndecan-2Colorectal cancerMeta-analysisSDC2

Identifiers

PMID35754025
PMCPMC9235166
OpenAlexW4283511027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.